FLT3 Specific Neutra™ Antibody Products

FMS-like tyrosine kinase 3 (FLT3) stands as a pivotal receptor tyrosine kinase, exerting critical roles within the hematopoietic system by regulating key cellular behaviors such as proliferation and differentiation. Its expression is concentrated in hematopoietic stem and progenitor cells, where its ligand FLT3 ligand (FL) induces dimerization and activates its intrinsic tyrosine kinase activity.

Structure and Function of FLT3

Comprising five domains, FLT3 gene transcription locates on chromosome 13q12. Its expression is restricted to early hematopoietic cells, predominantly found in human bone marrow or lymphoid progenitor cell populations and hematopoietic stem cells, but not in mature cells.

Fig.1 Genomic structure of FLT3¹

Binding with its ligand FL induces FLT3's autophosphorylation, initiating multiple signal transduction pathways including PI3K and RAS cascades, thereby promoting hematopoietic cell maturation and proliferation. Collaborating with other cytokines, it further modulates biological effects.

FLT3 and Diseases

• FLT3 and Acute Myeloid Leukemia (AML)

FLT3's dysregulated activity is associated with AML. Its relationship with AML has been extensively studied, being the most common genetic alteration in AML, with approximately one-third of patients carrying FLT3 mutations, including internal tandem duplications, point mutations, or deletions. Research has also shown a correlation between FLT3 and poor prognosis in AML patients, making FLT3 a potential prognostic biomarker and novel therapeutic target.

Fig.2 FLT3 structure and signaling.²

• FLT3 and Other Diseases

Besides AML, FLT3's overactivity is implicated in the occurrence and progression of other diseases. For instance, studies indicate FLT3's involvement in the pathogenesis of rheumatoid arthritis (RA). Therefore, therapeutic strategies targeting FLT3 may not be limited to AML but could also play a significant role in treating other autoimmune diseases.

• Application of FLT3 in Therapy

Therapeutic strategies targeting FLT3 have become integral to treating patients with acute myeloid leukemia. Currently, a range of FLT3 inhibitors, including various small molecule inhibitors and antibody drugs, are under development. These inhibitors disrupt FLT3 signaling pathway activity, inhibiting leukemia cell growth and proliferation, thereby providing new therapeutic opportunities. In addition to serving as promising disease intervention options, FLT3 antibodies also aid in exploring the mechanisms of FLT3 in cell signaling and disease pathogenesis, laying a theoretical foundation for drug development.

Fig.3 FLT3 inhibitors.³

Our Services

FLT3 plays a crucial role in the occurrence and development of various diseases, emerging as a new target for research and therapy. Creative Biolabs is committed to providing excellent FLT3 antibody products to researchers worldwide, leveraging our robust neutralizing antibody platform and recombinant antibody platform to offer new perspectives and possibilities for exploring its biological functions, pathogenesis, and therapeutic strategies. We will continue to monitor the latest developments in the FLT3 field, providing more possibilities for scientific research and clinical treatment. Please feel free to reach out to us for more information.

REFERENCES

1. Kazi, Ronnstrand, et al. "FMS-like tyrosine kinase 3/FLT3: from basic science to clinical implications." Physiol Rev. 99 (2019): 1433-1466.
2. Zhao, Agarwal, et al. "A Review of FLT3 Inhibitors in Acute Myeloid Leukemia." Blood Rev. 52 (2022): 1009905.
3. Daver, Schlenk, et al. "Targeting FLT3 mutations in AML: review of current knowledge and evidence." Leukemia 33 (2019): 299-312.